{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:19Z","timestamp":1790375359940,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>The rising prevalence of obesity presents significant challenges in managing chronic myeloid leukemia (CML). Bariatric surgery alters the bioavailability of oral medications, necessitating tailored treatment strategies for obese CML patients. This review aims to summarize the existing literature regarding CML management in patients with obesity and related surgeries, providing novel recommendations for their medical and surgical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A narrative review was performed, analyzing English-language articles published up to 2024. Key aspects considered included the impact of obesity and surgery on the pharmacokinetics (PK) of tyrosine kinase inhibitors (TKIs), potential drug-drug interactions (DDIs) with weight loss medications, and the role of therapeutic drug monitoring (TDM). The review also examined the implications of obesity on CML patient outcomes and treatment milestones, aiming to establish a pathway for managing these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results\/Discussion<\/jats:title><jats:p>Clinical data on CML management in obese patients is limited. Gastric bypass surgery may impair TKI efficacy due to reduced gastric acid secretion, affecting drug absorption. Adjustments like deflating gastric bands may enhance TKI absorption. The concurrent use of proton pump inhibitors can significantly lower the efficacy of certain TKIs, while others can be safely co-administered. Notably, patients with prior bariatric surgery show delayed treatment response milestones and may require TKI dose adjustments based on molecular responses rather than TDM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with CML planning bariatric surgery should receive comprehensive preoperative counseling regarding its effects on TKI therapy. Achieving deep remission pre-surgery is advisable, and delaying procedures when malabsorption is anticipated may enhance treatment outcomes. A multidisciplinary approach is essential in considering weight-loss medications, with further research needed to optimize TKI dosing in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1616883","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:19:13Z","timestamp":1751624353000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review"],"prefix":"10.3389","volume":"15","author":[{"given":"Rola","family":"Ghasoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basant","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Benkhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmarasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Adel","family":"Elsabagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Elmakaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0274","article-title":"Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden","volume":"67","author":"Fernberg","year":"2007","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v122:6","article-title":"Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies","volume":"122","author":"Larsson","year":"2008","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood.V118.21.3588.3588","article-title":"Association between obesity\/overweight and leukemia: A meta-analysis of prospective cohort studies","volume":"112","author":"Reagan","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.11.004","article-title":"Overweight, obesity and risk of haematological Malignancies: a cohort study of Swedish and Finnish twins","volume":"45","author":"S\u00f6derberg","year":"2009","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.12.020","article-title":"Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies","volume":"36","author":"Castillo","year":"2012","journal-title":"Leuk Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0028","article-title":"Obesity, weight gain, and risk of chronic myeloid leukemia","volume":"18","author":"Strom","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.053","article-title":"Drug dosing in obese adults","volume":"40","author":"Barras","year":"2017","journal-title":"Aust Prescr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3738","article-title":"How I treat obesity and obesity related surgery in patients with chronic myeloid leukemia: An outcome of an ELN project","volume":"9","author":"Yassin","year":"2021","journal-title":"Clin Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360180095016","article-title":"Renal disease in patients with massive obesity","volume":"146","author":"Kasiske","year":"1986","journal-title":"Arch Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/ijn.IJN_61_17","article-title":"Obesity and kidney disease: Hidden consequences of the epidemic","volume":"27","author":"Kovesdy","year":"2017","journal-title":"Indian J Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05924-4","article-title":"Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series","volume":"103","author":"Lau","year":"2024","journal-title":"Ann Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz045","article-title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies","volume":"30","author":"Abar","year":"2019","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.12.018","article-title":"Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib","volume":"333","author":"Breccia","year":"2013","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2018.182.issue-3","article-title":"Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors","volume":"182","author":"Molica","year":"2018","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"107609","DOI":"10.1016\/j.leukres.2024.107609","article-title":"The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis","volume":"147","author":"Isfort","year":"2024","journal-title":"Leuk Res"},{"key":"B24","unstructured":"The FDA Adverse Events Reporting System (FAERS) Public Dashboard\n          \n          2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1163137","article-title":"A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"10","author":"Kaddoura","year":"2023","journal-title":"Front Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1249401","article-title":"Association between visceral obesity and 10-year risk of first atherosclerotic cardiovascular diseases events among American adults: National Health and Nutrition Examination Survey","volume":"10","author":"Zheng","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1025392","article-title":"A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia","volume":"9","author":"Ahmed","year":"2022","journal-title":"Front Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7570\/jomes20065","article-title":"Optimal diet strategies for weight loss and weight loss maintenance","volume":"30","author":"Kim","year":"2021","journal-title":"J Obes Metab Syndr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1177\/10732748211009256","article-title":"Effects of intermittent fasting on response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia: an outcome of European leukemiaNet project","volume":"28","author":"Yassin","year":"2021","journal-title":"Cancer Control"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30069-3","article-title":"Clinical implications of food-drug interactions with small-molecule kinase inhibitors","volume":"21","author":"Veerman","year":"2020","journal-title":"Lancet Oncol"},{"key":"B31","unstructured":"Highlights of prescribing information: GLEEVEC (imatinib mesylate) tablets for oral use\n          \n          2017"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01428-6","article-title":"Clinical pharmacology of asciminib: A review","volume":"63","author":"Hoch","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"B33","unstructured":"Highlights of Prescribing Information: SCEMBLIX (asciminib) tablets\n          \n          2021"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i19.4504","article-title":"Long-term effectiveness, outcomes and complications of bariatric surgery","volume":"11","author":"Gulinac","year":"2023","journal-title":"World J Clin Cases"},{"key":"B35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13668-023-00498-5","article-title":"The effects of bariatric surgery on pharmacokinetics of drugs: a review of current evidence","volume":"12","author":"Konstantinidou","year":"2023","journal-title":"Curr Nutr Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1133415","article-title":"Effects of bariatric surgery on drug pharmacokinetics-Preclinical studies","volume":"14","author":"Mercado","year":"2023","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.9.1152","article-title":"Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia","volume":"29","author":"Pavlovsky","year":"2009","journal-title":"Pharmacotherapy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.532890","article-title":"Reduction of imatinib absorption after gastric bypass surgery","volume":"52","author":"Liu","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2019.09.003","article-title":"Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery","volume":"42","author":"Centrone","year":"2020","journal-title":"A Case Rep Hematol Transfus Cell Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1182\/blood.V130.Suppl_1.5260.5260","article-title":"Second generation tyrosisne kinase inhibitors as upfront therapy in the era of sleeve gastrectomy does it work","author":"Yassin","year":"2017","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v129.12","article-title":"Association between bariatric surgery and outcomes in chronic myeloid leukemia","volume":"129","author":"Haddad","year":"2023","journal-title":"Cancer"},{"key":"B42","volume-title":"Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy for Obesity Management","author":"Pedersen","year":""},{"key":"B43","unstructured":"Highlights of prescribing information: QSYMIA (phentermine and topiramate extended-release capsules)\n          \n          2022"},{"key":"B44","unstructured":"Highlights of prescribing information: PHYRAGO (dasatinib) tablets, for oral use\n          \n          \n          \n          2023"},{"key":"B45","volume-title":"Highlights of prescribing information: TASIGNA","year":"2020"},{"key":"B46","unstructured":"Green tea: purported benefits, side effects & more\n          \n          \n          \n          2024"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.13049","article-title":"Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing","volume":"39","author":"Maroselli","year":"2025","journal-title":"Fundam Clin Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.sla.0000137343.63376.19","article-title":"Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients","volume":"240","author":"Christou","year":"2004","journal-title":"Ann Surg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12869","article-title":"The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review","volume":"20","author":"Angeles","year":"2019","journal-title":"Obes Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122111","article-title":"The effects of bariatric surgery and gastrectomy on the absorption of drugs, vitamins, and mineral elements","volume":"13","author":"Miedziaszczyk","year":"2021","journal-title":"Pharmaceutics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.8.1077","article-title":"The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia","volume":"27","author":"Conti","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0503-3","article-title":"Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options","volume":"56","author":"van Leeuwen","year":"2017","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1616883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:19:17Z","timestamp":1751624357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1616883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":56,"alternative-id":["10.3389\/fonc.2025.1616883"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1616883","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"1616883"}}